Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Henrik H. Hansen, Michael Feigh, Sanne Skovgård Veidal, et al.
Drug Discovery Today (2017) Vol. 22, Iss. 11, pp. 1707-1718
Open Access | Times Cited: 218

Showing 26-50 of 218 citing articles:

Hepatoprotective effect of dihydroxy piperlongumine in high cholesterol-induced non-alcoholic fatty liver disease zebrafish via antioxidant activity
B. Haridevamuthu, Seenivasan Boopathi, P. Snega Priya, et al.
European Journal of Pharmacology (2023) Vol. 945, pp. 175605-175605
Closed Access | Times Cited: 23
Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis
Haressh Sajiir, Sahar Keshvari, Kuan Yau Wong, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Kupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult
Giada Di Nunzio, Sanna Hellberg, Yuyang Zhang, et al.
Nature Cardiovascular Research (2024) Vol. 3, Iss. 3, pp. 356-371
Open Access | Times Cited: 9
Multi-omics analysis of multiple missions to space reveal a theme of lipid dysregulation in mouse liver
Afshin Beheshti, Kaushik Chakravarty, Homer Fogle, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 75
Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
Lucia Kořínková, Veronika Pražienková, Lucie Černá, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 66
Effects of Propolis Extract and Propolis-Derived Compounds on Obesity and Diabetes: Knowledge from Cellular and Animal Models
Hiroshi Kitamura
Molecules (2019) Vol. 24, Iss. 23, pp. 4394-4394
Open Access | Times Cited: 56
The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model
Philipp Schwabl, Eva Hambruch, Grant R. Budas, et al.
Biomedicines (2021) Vol. 9, Iss. 1, pp. 60-60
Open Access | Times Cited: 56
Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis
Seonghwan Hwang, Hwayoung Yun, Sungwon Moon, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 56
NAFLD Preclinical Models: More than a Handful, Less of a Concern?
Yvonne Oligschlaeger, Ronit Shiri‐Sverdlov
Biomedicines (2020) Vol. 8, Iss. 2, pp. 28-28
Open Access | Times Cited: 55
The L‐α‐Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis
Marcos F. Fondevila, Uxia Fernandez, Maria J. González-Rellan, et al.
Hepatology (2020) Vol. 73, Iss. 2, pp. 606-624
Open Access | Times Cited: 55
Exercise Intervention Mitigates Pathological Liver Changes in NAFLD Zebrafish by Activating SIRT1/AMPK/NRF2 Signaling
Yunyi Zou, Zhanglin Chen, Chen‐Chen Sun, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 10940-10940
Open Access | Times Cited: 49
Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
John J. Nestor, David G. Parkes, Michael Feigh, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 35
Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions
Melissa Myint, Francesca Oppedisano, Valeria De Giorgi, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 22
Faecalibacterium prausnitzii prevents hepatic damage in a mouse model of NASH induced by a high-fructose high-fat diet
Ji‐Hee Shin, Yoonmi Lee, Eun‐Ji Song, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 21
Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease
Jakub Rochoń, Piotr Kalinowski, Ksenia Szymanek-Majchrzak, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 23, pp. 2964-2980
Open Access | Times Cited: 8
Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice
Hyunghee Lee, Jiwon Ahn, Soon Shik Shin, et al.
International Journal of Obesity (2018) Vol. 43, Iss. 8, pp. 1620-1630
Closed Access | Times Cited: 59
Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?
David Højland Ipsen, Jens Lykkesfeldt, Pernille Tveden‐Nyborg
Advances in Nutrition (2020) Vol. 11, Iss. 6, pp. 1696-1711
Open Access | Times Cited: 47
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
Jonathan D. Roth, Sanne Skovgård Veidal, Louise K. D. Fensholdt, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 44
Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis
Noha F. Hassan, Somaia A. Nada, Azza Hassan, et al.
Inflammation (2019) Vol. 42, Iss. 3, pp. 1056-1070
Closed Access | Times Cited: 43
Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice
Maria Guarino, Pavitra Kumar, Andrea Felser, et al.
Cancers (2020) Vol. 12, Iss. 6, pp. 1407-1407
Open Access | Times Cited: 40
Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease
Jiashu Pan, Wenjun Zhou, Ruohui Xu, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113127-113127
Open Access | Times Cited: 28
Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis
Zhiqi Feng, Jiehao Xiang, Hui Liu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 3, pp. 2571-2592
Closed Access | Times Cited: 25
UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis
Tao Zhang, Na Zhang, Jing Xing, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Nobiletin Ameliorates Hepatic Lipid Deposition, Oxidative Stress, and Inflammation by Mechanisms That Involve the Nrf2/NF-κB Axis in Nonalcoholic Fatty Liver Disease
Chaowen Fan, Anli Ling-Hu, Dali Sun, et al.
Journal of Agricultural and Food Chemistry (2023) Vol. 71, Iss. 50, pp. 20105-20117
Closed Access | Times Cited: 16
Theabrownin ameliorates liver inflammation, oxidative stress, and fibrosis in MCD diet-fed C57BL/6J mice
Qingcai Zhen, Qijian Liang, Hongchun Wang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 15

Scroll to top